Literature DB >> 28769214

CHANGING TRENDS OF LEPROSY IN ARMED FORCES.

P N Arora1, S Grover2.   

Abstract

A total of 651 cases of leprosy were hospitalised from Jan 1987 to Dec 1992. Each patient underwent haemogram, total and differential white cell count, urinalysis, liver function tests, skin slit smear for AFB and skin biopsy. Nerve conduction studies, electomyographic studies and nerve/nerve sheath biopsies were undertaken as and when indicated. These patients were managed with multidrug therapy. Paucibacillary (PB) leprosy accounted for 476 (73.1%) cases which comprised of indeterminate leprosy 90 (13.8%), tuberculoid leprosy 14 (2.2%), borderline tuberculoid leprosy 310 (47.6%) and neuritic leprosy 62 (9.5%). The remaining 175 patients (26.9%) were multibacillary (MB) which included borderline leprosy 9 (1.4%), borderline lepromatous leprosy 129 (19.8%) and lepromatous leprosy 37 (5.7%) patients. There were total 153 patients in 1987. This number declined to 44 in 1992. PB declined from 113 in 1987 to 39 in 1992 and MB cases from 40 to 5.

Entities:  

Keywords:  Leprosy

Year:  2017        PMID: 28769214      PMCID: PMC5529772          DOI: 10.1016/S0377-1237(17)31081-X

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  4 in total

1.  Reduction in caseload after multidrug therapy in an urban leprosy control programme--a retrospective study in Bombay.

Authors:  C R Revankar; P L Pawar; L S Belurkar; R R Pai; R Ganapati
Journal:  Lepr Rev       Date:  1991-03       Impact factor: 0.537

Review 2.  Control of leprosy in India in the background of urbanization.

Authors:  R Ganapati
Journal:  Indian J Lepr       Date:  1991 Jul-Dec

3.  Epidemiology of leprosy in relation to control. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1985

Review 4.  Leprosy: the epidemiology of a slow bacterium.

Authors:  P E Fine
Journal:  Epidemiol Rev       Date:  1982       Impact factor: 6.222

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.